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Primary care
Randomised controlled trial of an interactive multimedia
decision aid on benign prostatic hypertrophy in primary
care
Elizabeth Murray, Hilary Davis, Sharon See Tai, Angela Coulter, Alastair Gray, Andy Haines
Abstract
Objective To determine whether a decision aid on
benign prostatic hypertrophy influences decision
making, health outcomes, and resource use.
Design Randomised controlled trial.
Setting 33 general practices in the United Kingdom.
Participants 112 men with benign prostatic
hypertrophy.
Intervention Patients’ decision aid consisting of an
interactive multimedia programme with booklet and
printed summary.
Outcome measures Patients’ and general
practitioners’ perceptions of who made the decision,
decisional conflict scores, treatment choice and
prostatectomy rate, American Urological Association
symptom scale, costs, anxiety, utility, and general
health status.
Results Both patients and general practitioners found
the decision aid acceptable. A higher proportion of
patients (32% v 4%; mean difference 28%, 95%
confidence interval 14% to 41%) and their general
practitioners (46% v 25%; 21%, 3% to 40%) perceived
that treatment decisions had been made mainly or
only by patients in the intervention group compared
with the control group. Patients in the intervention
group had significantly lower decisional conflict scores
than those in the control group at three months (2.3 v
2.6; − 0.3, − 0.5 to − 0.1, P < 0.01) and this was
maintained at nine months. No differences were
found between the groups for anxiety, general health
status, prostatic symptoms, utility, or costs (excluding
costs associated with the video disc equipment).
Conclusions The decision aid reduced decisional
conflict in men with benign prostatic hypertrophy,
and the patients played a more active part in decision
making. Such programmes could be delivered cheaply
by the internet, and there are good arguments for
coordinated investment in them, particularly for
conditions in which patient utilities are important.
Introduction
The rationale for decision aids is addressed in the
accompanying paper.1 Unlike hormone replacement
therapy, prostate surgery is a “Rubicon” procedure—
that is, once undertaken it cannot be reversed. In the
United States, a pilot study on the impact of a
programme to aid in decisions about benign prostatic
hyperplasia showed a 40% decrease in surgery rates.2
This finding was not replicated in a subsequent
randomised controlled trial.3
We aimed to determine whether an interactive
multimedia decision aid in primary care would
promote greater patient involvement in decision mak›
ing and what influence this had on treatment choices
and health outcomes. We also aimed to determine the
acceptability of such a system to patients and general
practitioners and the impact on a general practitioner’s
workload and to undertake an economic analysis.
Participants and methods
Patient recruitment
We invited general practitioners in two urban areas
(Oxford and London), one suburban area (Harrow),
and one semirural area (Thame and the Chilterns) to
participate in our study.1 We asked participating
doctors to recruit men with benign prostatic hypertro›
phy opportunistically. The doctors were asked to retain
their normal clinical practice in diagnosing or manag›
ing the condition but to refer patients to the study as
soon as they were confident about the diagnosis. The
men needed a sufficient understanding of English to be
able to consult without an interpreter. Men were
excluded if there was any clinical suggestion of
carcinoma of the prostate or if they had chronic reten›
tion of urine, recent urinary tract infection, a history of
acute urinary retention or prostate surgery, severe
visual or hearing impairment, or severe learning
difficulties or mental illness. Ethical approval was
obtained from local research ethics committees.
Intervention
The intervention, developed by the Foundation for
Informed Medical Decision Making,4 comprised an
interactive multimedia programme with booklet and
printed summary. Information was obtained from
studies by the Patient Outcome Research Team and
other published trials.1 5 Treatment options discussed
were surgery (prostatectomy or transurethral prosta›
tectomy), balloon dilatation of the prostate, drugs (á2
blockers and 5á reductase inhibitors), and watchful
waiting. Information comprised probabilities of the
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Example of printout given to each patient after viewing the programme
Benign Prostatic Hyperplasia: Choosing Surgical or Non Surgical Treatment
Summary for: John Smith
The treatment options discussed in this program you have just seen are:
1. Surgical Treatment, which includes three approaches:
• Prostatectomy
• Transurethral incision of the prostate or TUIP
• Balloon dilation of the prostate
2. Non Surgical Treatment, which includes two approaches:
• Watchful waiting
• Taking medication
• Alpha Blockers (several are available)
• Reductase inhibitors (Finasteride is the only one now available)
Important Message: This is a decision to be taken by you and your doctor. How you decide depends on how you feel about your
symptoms and how you feel about the possible harms and benefits of the surgical approaches compared to the possible harms and benefits
of non›surgical approaches. Not every man is a good candidate for all possible benign prostatic hyperplasia treatments. Your doctor can
help explain which treatment would be possible in your situation.
We have summarised the main messages presented in the programme below:
Possible Benefits of the Treatment Options
1. The Surgical Options:
• With prostatectomy and the TUIP there is a good chance for substantial reduction of symptoms. For men with your moderate symptoms
by the end of one year, 79% of men have only mild symptoms. Another 15% have moderate symptoms and 6% are putting up with severe
symptoms.
With balloon dilation 40›70% of men appear to have some symptom improvement soon after, however, the benefits don’t last as long as
prostatectomy and the TUIP. Only 30% of men followed for two or three years after balloon dilation are still improved. With balloon
dilation there can be a reduction in symptoms, but seldom for as long as with prostatectomy or TUIP.
• There is less chance of future prostate problems such as acute retention, urinary tract infection and bladder and kidney damage, after
prostatectomy and TUIP.
2. The Non›Surgical Options:
• With watchful waiting, there is a chance that symptoms may improve on their own. For men with your moderate symptoms, by the end of
one year, 28% of men have only mild symptom. Another 47% have moderate symptoms and 16% are putting up with severe symptoms.
Possible Harms of the Treatment Options
1. The Surgical Options
For men who choose a prostatectomy:
• Chance of death: for men in your age group, 4 out of 1000 will die (which means that 996 out of 1000 will survive) within 6 weeks of
surgery; however, not all these deaths are due to surgery.
• Medical complications: about 1% of men will experience medical complications such as a heart attack, stroke, pneumonia or blood clot in
the lungs.
• Readmission: about 8% of men require readmission to the hospital for a prostate related problem within 3 months following surgery.
• Incontinence: up to 1% of men experience complete loss of control of urine, while 4% of men indicate some partial loss of control.
• Sexual problems: between 60% and 100% of men experience retrograde ejaculation. About 5% of men consistently have problems
getting an erection, while 10›20% have some intermittent problems getting erections after surgery
• Reoperation: 4›10 % of men will need another operation in the five years following their first prostatectomy.
Risks of TUIP compared to prostatectomy:
• Bleeding and medical complications happen less often than with a prostatectomy.
• Incontinence may also be less common and retrograde ejaculation happens in only 15 › 40 % of men who have a TUIP
• Stricture is less common after TUIP. Although reoperation rates aren’t well studied for TUIP, some experts worry that the risk of
reoperation may be higher because no prostate tissue is removed.
For men who chose a balloon dilation:
• Bleeding and medical complications happen less often than with the other surgical treatments.
• Incontinence is possible, although cases have been extremely rare, and retrograde ejaculation together with impotence although not well
studied also appear to be rare.
• There is no evidence that this procedure reduces the risks of acute retention, urinary tract infection or bladder and kidney damage when
compared to prostratectomy or TUIP.
2. The Non›Surgical Options
For men who choose watchful waiting:
• There may be an increase in the risks associated with surgery if you decide to have surgery in the future. For men with your symptoms
about 9% will decide to have surgery over a one year period.
• Acute retention will occur in about 7% of men over 5 years, and serious urinary tract infection will occur in less than 2% of men in 5
years
• Kidney or bladder damage can occur, but the risk appears to be very low with regular physicians visits to monitor your condition
For men who choose medication:
• All medications for BPH carry with them some chance of side effects. Dizziness, tiredness, and weakness are the main possible side effects
of the alpha blockers. With reductase inhibitors, about 4% of men have problems with sexual function. Any side effects should eventually go
away if you stop taking the drug.
• There is very little information available about the side effects of medications for BPH taken for more than a year.
• Alpha blockers must be used cautiously in men with some other medical problems, and by those taking some other medications.
Please think about the choices, the advantages and the disadvantages, and how you feel personally about the options. Please talk with your physician about your
particular circumstances so that you and your doctor can make the best choice for you. Whatever you and your doctor decide, it is important that you have
careful follow›up after you treatment. Ask you doctor what he or she recommends for follow›up monitoring.
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risks and benefits of each treatment, calculated on the
basis of information on age, severity of symptoms, and
general health entered by the patient at the beginning
of the session. After viewing the programme the
patients were given a summary of the information
(box); a copy was also sent to their general
practitioners.
As the programme used interactive video disc tech›
nology, since superseded by CD Rom and web based
interactive programmes, we imported specialised
hardware from the United States. Patients travelled to
one of five sites, chosen for ease of access from
referring practices, to view the programme in a private
room. All the patients saw the core programme, lasting
about 45 minutes; viewing optional sections for further
information took up to 60 minutes more. A research
nurse started the programme, taught the patient how
to use it, and then withdrew.
Randomisation
Patients randomised to the control group received
normal care from their general practitioner. Randomi›
sation was performed after informed consent had been
obtained. The randomisation schedule, stratified
according to recruitment centre, was generated by
computer. Allocations were sealed in opaque num›
bered envelopes, opened by the study nurse after
collection of the baseline data.
Data collection
We collected baseline data before randomisation.
Follow up data were collected by postal questionnaire
from patients three and nine months after baseline.
Outcome measures included personal details, patients’
and general practitioners’ perceptions of who made
the decision about treatment, patient’s satisfaction with
the choice of treatment, decisional conflict scores,6
choice of treatment and prostatectomy rate, health sta›
tus and physical function (SF›36),7 health states and
valuation of health states (Euroqol EQ›5D),8 anxiety
(Spielberger state trait anxiety inventory short form),9
and prostatic symptoms (American Urological Associ›
ation symptom scale).10 Patients in the intervention
group completed a questionnaire immediately after
viewing the programme. All patients were asked to see
their doctor to reach a treatment decision.
After the follow up consultation the general practi›
tioners filled in a questionnaire to determine the time
spent on the consultation, their perceptions of who
made the treatment decision and whether the
programme had helped or hindered the consultation
for patients in the intervention group.
Economic evaluation
We recorded the resources used by each patient over
the trial period. These were the equipment and staff
time associated with video sessions, the number and
duration of consultations with the general practition›
ers, referrals to urologists, other referrals, drugs related
to benign prostatic hypertrophy, tests, and diagnostic
and surgical procedures. The unit costs were attached
to resource volumes to obtain a total cost per patient.
Table 1 shows the unit costs used in the analysis and
the sources of information. To aid generalisability of
the results we obtained unit costs from national
sources where possible.
We measured utility with the Euroqol EQ›5D at
baseline and at three and nine months. Valuations of
health states were taken from the UK population
tariff.11 We compared point values, summed values over
the trial, and changes from baseline to the end of the
trial. The box shows the costs of the technology used in
the trial; these are not included in the baseline analysis,
as an alternative and much less costly delivery system is
now available for presenting the same content. We
conducted our economic evaluation from the perspec›
tive of the healthcare system. All costs are in pounds
sterling at 1999 prices.
Sample size
We postulated that patients with more information
would tolerate greater intensity of symptoms without
seeking active treatment, as preliminary results from
the United States showed a reduced uptake of surgery
in the intervention group.2 Additionally, a concern
commonly voiced by general practitioners during the
developmental phase of the trial was that the interven›
tion could raise patients’ anxiety. A sample size of 160
patients (80 in each group) would have given us 90%
power to detect a difference of 3.7 points (from 15 to
18.7) in the mean scores on the American Urological
Association symptom scale for the two groups and 6
points (from the baseline mean score of 32 to 38) on
the Spielberger state trait anxiety inventory at the 5%
level of significance. Allowing for a 30% dropout rate,
we planned to recruit 210 patients; however, both
recruitment and dropout rates were less than expected
(figure). A retrospective calculation determined that
the power to detect the observed difference in
decisional conflict score between the two groups at the
final assessment was 85% at the 5% significance level.
As recruitment was slower than anticipated, we
monitored consultations at one large computerised
practice and also identified all patients referred to a
local ultrasound department for ultrasonography of
the prostate to see whether eligible patients were
attending participating general practitioners but not
being referred to the study. We were unable to find any
missed cases.
Table 1 Unit costs in pounds sterling (at 1999 prices) and sources of information used
in economic evaluation
Item Unit cost Source
Generic consultation with doctor 14.00 Department of Health
Doctor’s cost per minute 1.62 Department of Health
Urology consultation 56.46 English average from trust’s
financial return 2 data
Tests:
Urine (microscopy and culture) 6.00 Average from five trusts
Prostatic specific antigen 28.17 Average from five trusts
Ultrasound 12.00 Average from five trusts
Cystoscopy 35.00 Average from five trusts
Urinary flow 24.00 Average from five trusts
Biopsy 55.00 Average from five trusts
Transurethral prostatectomy 1795.00 Average from five trusts
Drugs:
Finasteride 5 mg/day (28 pack of 5 mg) 24.90 British National Formulary
Prazosin 5 mg/day (56 pack of 500 ìg) 2.09 British National Formulary
Indoramin 5 mg/day, 20 mg twice daily (60 pack) 12.30 British National Formulary
Tolterodine 1 mg/day, 2 mg twice daily (56 pack) 32.00 British National Formulary
Interactive decision aid session 283.85 See box
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Statistical analysis
We analysed data for all outcomes for those patients
who completed all the assessments. We also performed
an intention to treat analysis to allow for those patients
who did not complete the study and who were
therefore unable to provide data at the nine months’
assessment. For that analysis we assumed no change in
score on any outcome from the beginning of the study,
and we substituted baseline data for the missing data at
the final assessment. Where data for resource use were
missing for the second follow up only or for individual
resource items, we took the mean value for that item in
that arm of the study. We present the results for those
who completed the nine months’ assessment, as the
intention to treat analysis did not alter the results.
We compared the change in scores for the Ameri›
can Urological Association and Spielberger scales
from baseline to final assessment between the study
groups. We compared the decisional conflict scores
between the two groups at three and nine months, as
we hypothesised that decisional conflict would be
greater closer to the decision making process. We per›
formed Mann›Whitney U tests when data for outcome
measures were skewed (as detected by Kolmogorov›
Costs of trial technology
Video disc systems were installed in five locations. The
video hardware systems were obtained at a cost of
£24 300. No insurance or maintenance costs were
incurred, but each system had to be kept in a secured
room, a locked cupboard, or a combination of these.
Arrangements for use of space to store and use the
equipment varied between centres, but a total of
£3070 was paid over the five centres for storage and
room rental.
Software for the disc players was obtained from the
Foundation for Informed Decision Making. The cost
of software was $1900 (£1118) per video disc, giving a
total cost of $9500 (£5590) plus £400 for shipping and
insurance.
Because of technological change during the study,
the equipment had no residual value by the end of the
study. However, the equipment was shared with
another trial,1 and in terms of patient numbers only
36% of the costs for equipment were attributable to
the current study. The total equipment and storage
costs were therefore £15 840.
Trial research nurses took patients to the video
rooms, set up the equipment and explained its
operation, and returned at the end of the session to
put the equipment away. Diaries were maintained at
one site for a sample period of one month, and from
these it was estimated that 25 minutes of staff time was
involved per viewing session. Based on a research
nurse being on F grade, the cost of this time was £5.85
per session.
A total of 57 patients in the current trial used the
equipment across the five centres. The cost per patient
was therefore £278 for the equipment plus £5.85 for
staff time, a total of £283.85 per video session.
Patients referred to study by general practitioner (n=159)
Control group
Received intervention as allocated
(n=55)
Not eligible (n=17)
Unable to contact (n=13)
Dropped out (n=7):
  Withdrew (n=5)
  Did not have benign
  prostatic hypertrophy (n=2)
Dropped out (n=3):
  Death (n=1)
  Withdrew (n=2)
Not randomised (n=17):
  Declined, reason not given (n=7)
  Declined, awaiting test results (n=1)
  Taking part in other research (n=1)
  Too far to travel (n=2)
  Concurrent health problems (n=1)
  Family advised against (n=1)
  Failed to attend appointment (n=3)
  Died before recruitment (n=1)
Intervention group
Received intervention as allocated
(n=57)
Completed trial (n=48)Completed trial (n=54)
Follow up at 3 months (n=49)Follow up at 3 months (n=57)
Randomised (n=112)
Progress of patients through trial
Table 2 Baseline characteristics of participants. Values are numbers (percentages) of
men unless stated otherwise
Characteristic
Intervention group
(n=57)
Control group
(n=55)
Ethnicity (white) 53 (93) 52 (95)
Educational attainment:
Up to secondary education 25 (44) 28 (51)
Beyond secondary education 32 (56) 27 (49)
Treatment choice:
Watchful waiting 10 (18) 10 (18)
Prescribed drug by doctor 13 (23) 8 (15)
Referred to specialist 7 (12) 6 (11)
Let doctor decide 14 (25) 16 (29)
Unsure 13 (23) 15 (27)
Mean (SD) American Urological Association score 15.64 (6.57) 14.85 (7.10)
Mean (SD) age (years) 63.7 (8.4) 63.9 (8.4)
Mean (SD) decisional conflict:
Uncertainty 3.2 (0.8) 3.0 (0.7)
Factors contributing to uncertainty 2.8 (0.15) 2.9 (0.5)
Mean (SD) Spielberger state trait anxiety inventory 33.93 (13.09) 32.01 (10.49)
Mean (SD) EQ›5D:
Visual analogue scale 71.3 (21.5) 78.2 (13.9)
Tariff 0.83 (0.23) 0.84 (0.16)
Table 3 Acceptability of decision aid to patients
No (%) of patients
Was the video easy to understand?
Very easy 41 (72)
Quite easy 16 (28)
Quite difficult 0
Very difficult 0
Do you think the video was:
Very interesting 43 (75)
Quite interesting 14 (25)
Uninteresting 0
Boring 0
Effect on understanding of prostate problem
Understand more 49 (86)
Understanding unchanged 8 (14)
Understand less 0
Effect on difficulty of decision making
Easier to decide 44 (77)
Neither easier nor harder 11 (19)
Harder to decide 2 (4)
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Smirnov and Shapiro Wilk tests for assessing the nor›
mality of data). We present the means and standard
deviations for resource use and costs; confidence inter›
vals around mean differences between study groups
are based on t tests assuming unequal variances.
Results
Recruitment
Overall, 33 general practices agreed to participate; 12
from Oxford and the Chilterns and 21 from London
and Harrow. Between January 1996 and September
1998, 112 men were recruited (figure). Table 2 presents
the baseline data on the two groups.
Impact on decision making
Patients reacted positively to the decision aid (table 3).
At three months, patients in the intervention group
showed lower decisional conflict on all three subscales
and on their total score (table 4); this significant differ›
ence was maintained at the final assessment (total score
at nine months: mean (SD) scores, intervention group
2.23 (0.38), control group 2.55 (0.50); mean difference
− 0.33, 95% confidence interval for mean difference
− 0.51 to − 0.14). A higher proportion of both general
practitioners and patients perceived that treatment
decisions had been made mainly or only by the
patients in the intervention group (table 5).
General practitioners were positive about the deci›
sion aid; of 50 follow up consultations with patients in
the intervention group they said that the decision aid
had helped in 46, made no difference in three, and
hindered in one.
Anxiety and other health status outcomes
The Spielberger scores were similar at the final assess›
ment in the two groups (Mann›Whitney U test). The
American Urological Association scores in both
groups improved over the study period. The amount of
change was not significantly different in the two groups
(median change in score − 1 in intervention group, − 2
in control group; Mann›Whitney U test, P = 0.8). We
found no difference between the two groups in the
trends over time in the EQ›5D responses nor in the
SF›36 scores.
Economic evaluation
Missing data were replaced by conditional means in
less than 4% of resource use items. No significant
differences were detected in resource volumes used per
patient between the groups (table 6).
Table 7 shows cost per patient by allocation. When
costs of the video sessions were excluded, there was no
significant difference in total or individual costs of the
components between groups. When costs associated
with these sessions were included the total cost per
Table 4 Decisional conflict score at three months. Values are means (SDs) unless
stated otherwise
Intervention
group Control group Mean difference (95% CI)
Uncertainty 2.4 (0.8) 2.7 (0.8) −0.3 (−0.6 to 0.0)
Factors contributing to uncertainty 2.3 (0.5) 2.7 (0.6) −0.4 (−0.7 to −0.2)**
Perceived effective decision making 2.0 (0.4) 2.2 (0.6) −0.2 (−0.4 to −0.002)*
Total decisional conflict score 2.3 (0.4) 2.6 (0.5) −0.3 (−0.5 to −0.1)**
The decisional conflict scale contains three subscales that elicit uncertainty about choosing between
alternatives, awareness of modifiable factors contributing to the uncertainty, and perceived effectiveness of
decision making process. Higher scores indicate increased uncertainty in each subscale. Subscales can be
combined to give a total decisional conflict score. Subjects with strong intentions to accept or decline a
health intervention tend to lower scores and those who remain uncertain tend to higher scores.12 *P<0.05.
**P<0.01.
Table 5 General practitioners’ and patients’ perceptions of decision making at three
months. Values are numbers (percentages) of patients unless stated otherwise
Intervention
group Control group % difference (95% CI)
General practitioners (n=48) (n=49)
Who do you think made the treatment decision?:
Mainly or only general practitioner 1 (2) 5 (10) −8 (−17.5 to 1.3)
General practitioner and patient together 25 (52) 32 (65) −13 (−32.6 to 6.2)
Mainly or only patient 22 (46) 12 (25) 21 (2.8 to 39.9)
÷2=6.458, df=2; P=0.04
Patients (n=57) (n=48)
Who do you think made the treatment decision?:
Mainly or only general practitioner 5 (9) 4 (8) 1 (−10.3 to 11.2)
General practitioner and patient together 34 (60) 42 (88) −28 (−43.7 to −12.0)
Mainly or only patient 18 (32) 2 (4) 28 (14.1 to 40.7)
÷2=13.078, df=2; P=0.001
Table 6 Resource volumes per patient by allocation over nine months of trial. Values
are means (SDs) unless stated otherwise
Resource item
Intervention
group (n=57)
Control group
(n=48) Mean difference (95% CI)
No of consultations:
General practitioner 2.27 (1.21) 2.32 (1.62) −0.05 (−0.61 to 0.51)
Urologist 0.42 (0.75) 0.55 (0.84) −0.13 (−0.44 to 0.163)
Other 0.14 (0.40) 0.22 (0.41) −0.08 (−0.23 to 0.08)
No of tests:
Urine 0.26 (0.52) 0.41 (0.57) −0.14 (−0.36 to 0.07)
Prostatic specific antigen 0.40 (0.62) 0.26 (0.43) 0.14 (−0.06 to 0.35)
Ultrasound 0.33 (0.61) 0.27 (0.49) 0.06 (−0.15 to 0.28)
Cystoscopy 0.04 (0.19) 0.02 (0.14) 0.01 (−0.05 to 0.08)
Urinary flow 0.25 (0.51) 0.30 (0.58) −0.06 (−0.27 to 0.16)
Biopsies 0.05 (0.23) 0.04 (0.20) 0.01 (−0.07 to 0.09)
No of prostatectomies or referrals for
prostatectomies
0.11 (0.31) 0.02 (0.14) 0.08 (−0.01 to 0.18)*
*P=0.12, ÷2 test of this item, two sided test of exact significance.
Table 7 Costs in pounds sterling (at 1999 prices) per patient, by allocation. Values are means (SDs) unless stated otherwise
Cost item
Intervention group
(n=57) Control group (n=48) Mean difference (95% CI)
Doctor appointments 50.2 (26.9) 56.7 (40.4) −6.5 (−20.1 to 7.2)
Urology consultations 23.8 (42.6) 30.9 (47.3) −7.1 (−24.7 to 10.5)
Other consultations 2.0 (5.6) 3.0 (5.8) −1.1 (−3.3 to 1.1)
Tests and investigative procedures 26.9 (36.9) 23.2 (25.8) 3.6 (−8.6 to 15.8)
Prostatectomies and referrals for prostatectomy 188.9 (555.8) 37.4 (259.1) 151.6 (−12.7 to 315.8)
Drugs 18.5 (90.1) 37.6 (86.7) −19.1 (−53.4 to 15.2)
Total costs, excluding intervention 310.3 (602.0) 188.8 (300.4) 121.5 (−58.9 to 302.0)
Total costs, including intervention 594.1 (602.0) 188.8 (300.4) 405.4 (224.9 to 585.8)***
***P<0.001.
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patient in the intervention group increased to £594,
compared with £199 in the control group (difference
£405, £225 to £586).
Discussion
The decision aid on benign prostatic hypertrophy
seemed to increase patients’ participation in decision
making. A higher proportion of both patients and gen›
eral practitioners thought that patients had “mainly or
only” made the treatment decisions themselves in the
intervention group than in the control group. Patients
who viewed the programme had reduced decisional
conflict scores (indicating reduced uncertainty about
the decision) at three months, and this was maintained
at nine months. The intervention was acceptable to
both the patients and the doctors. The general
practitioners were, however, likely to have had a prior
interest in shared decision making. Recently, general
practice registrars reported not being trained in the
skills required to involve patients in clinical decisions.13
The intervention did not reduce costs; six out of
seven completed or planned prostatectomies were in
the intervention group. These results make it unlikely
that the intervention reduced prostatectomy rates in a
UK general practice population, but the study was
underpowered to determine whether it caused an
increase in the surgical rate.
Methodological considerations
The low recruitment rate prevented us from defini›
tively determining that there was no increase in anxiety
in the intervention group; however, the intervention
had no noticeable impact on anxiety. The low
recruitment rate did not seem to be due to bias in
recruiting patients into the trial, as we were unable to
detect the non›referral of suitable patients attending
the study practices. Moreover, as randomisation
occurred after referral it would be unlikely to affect the
main conclusion of the study. Although the technology
used in these trials is now outdated, this does not affect
the main findings, which relate to the interactive multi›
media nature of the decision aid. The cost of delivering
such programmes by the internet to standard personal
computers would be small: equipment costs of £1500
over three years, with a low utilisation rate (two users
per weekday) and lower space and staff costs commen›
surate with a less dedicated technology would bring the
cost per session, excluding software, down from £177
to about £5 (£1 equipment, £2.50 staff time, £1.50
space).
Implications for the NHS
Internet sites for people seeking information on health
care are proliferating, but many are of low quality. The
NHS has the opportunity to provide high quality
patient information and decision aids through outlets
such as NHS Direct Online, with the potential to
enhance patient care through informed patient choice.
Accessible evidence based information for patients
could play an important part in the drive to promote
evidence based health care.
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What is already known on this topic
Patients want more information about their
condition and treatment options, and many want
to play an active part in decision making
Decision aids improve patients’ knowledge of their
conditions and treatment options
What this study adds
The decision aid was highly acceptable to both the
patients and their general practitioners
Decisional conflict was reduced in the intervention
group
Patients who viewed the programme played a
more active part in the decision making process
and were less anxious than control patients
Such aids could be introduced throughout the
NHS at relatively low cost by using the internet
Primary care
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